Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-ibritumomab Tiuxetan with RIC Allo-HCT in Advanced NHL
NCT00302757Phase 2Completed
- Sponsor
- University Hospital Tübingen
- Start
- Mar 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by University Hospital Tübingen. Primary endpoints: Treatment Related Toxicity and Engraftment. Started Mar 2006; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00302757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00302757.